机构：[1]Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sicuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China临床药学部临床药学部四川省人民医院四川省肿瘤医院[2]Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China[3]Department of Traditional Chinese Medicine Surgery, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu 610072, Sichuan, China四川省人民医院[4]Department of Gynecology and Obstetrics, Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, China四川省人民医院
Base editing technology, developed from the CRISPR/Cas9 system, is able to efficiently implement single base substitutions at specific DNA or RNA sites without generating double-strand breaks (DSBs) with precision and efficiency. Point mutations account for 58% of disease-causing genetic mutations in humans, and single nucleotide variants (SNVs) are an important cause of tumorigenesis, and the advent of base editors offers new hope for the study or treatment of such diseases. Although it has some limitations, base editors have been continuously improved in terms of editing efficiency, specificity and product purity since their development. In this review, we examine the main base editing technologies and discuss their applications and prospects in tumor research and therapy, as well as elaborate on their mode of delivery.
基金：
Science and Technology Program of
Sichuan Province (No. 2022NSFSC0792, 2020YFS0417); Beijing Xisike Clinical Oncology
Research (No. Y-QL202101-0125); Technology Innovation Research and Development Project of Chengdu Science and Technology Bureau (No. 2022-YF05-01591-SN)；
Foundation of Sichuan Province Key Laboratory of Individualized Drug Therapy （
No.2021YB03）; Research Project established by Chinese Pharmaceutical Association
Hospital Phamacy department (No.CPA-Z05-ZC-2022-002).
语种：
外文
被引次数：
WOS：
PubmedID：
中科院(CAS)分区：
出版当年[2023]版：
大类|3 区医学
小类|2 区生物工程与应用微生物3 区遗传学3 区医学：研究与实验
最新[2023]版：
大类|3 区医学
小类|2 区生物工程与应用微生物3 区遗传学3 区医学：研究与实验
JCR分区：
出版当年[2023]版：
Q1GENETICS & HEREDITYQ2BIOTECHNOLOGY & APPLIED MICROBIOLOGYQ2MEDICINE, RESEARCH & EXPERIMENTAL
最新[2023]版：
Q1GENETICS & HEREDITYQ2BIOTECHNOLOGY & APPLIED MICROBIOLOGYQ2MEDICINE, RESEARCH & EXPERIMENTAL
第一作者机构：[1]Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sicuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China[2]Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China
共同第一作者：
通讯作者：
通讯机构：[1]Department of Pharmacy, Sichuan Clinical Research Center for Cancer, Sichuan Cancer Hospital & Institute, Sicuan Cancer Center, Affiliated Cancer Hospital of University of Electronic Science and Technology of China, Chengdu, China[2]Personalized Drug Therapy Key Laboratory of Sichuan Province, Chengdu, China
推荐引用方式(GB/T 7714)：
Huang Lu,Yang Chao,Chen Yan,et al.CRISPR-Mediated Base Editing: Promises and Challenges for a Viable Oncotherapy Strategy[J].HUMAN GENE THERAPY.2023,34(15-16):669-681.doi:10.1089/hum.2023.045.
APA：
Huang Lu,Yang Chao,Chen Yan,Deng Han,Liao Zhi&Xiao Hongtao.(2023).CRISPR-Mediated Base Editing: Promises and Challenges for a Viable Oncotherapy Strategy.HUMAN GENE THERAPY,34,(15-16)
MLA：
Huang Lu,et al."CRISPR-Mediated Base Editing: Promises and Challenges for a Viable Oncotherapy Strategy".HUMAN GENE THERAPY 34..15-16(2023):669-681
